Literature DB >> 10440104

Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes.

J Cheng1, R Niwa, K Kamiya, J Toyama, I Kodama.   

Abstract

Carvedilol ((+/-)-1-(carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]am ino]-2-propanol), a beta-adrenoceptor-blocking agent with vasodilator properties, has been reported to produce dose-related improvements in left ventricular function and reduction in mortality in patients with chronic heart failure. However, its electrophysiological effects have not been elucidated. We studied ion channel and action potential modulation by carvedilol in rabbit ventricular preparations using whole-cell voltage-clamp and standard microelectrode techniques. In ventricular myocytes, carvedilol blocked the rapidly activating component of the delayed rectifier K+ current (I(Kr)) in a concentration-dependent manner (IC50 = 0.35 microM). This block was voltage- and time-independent; a prolongation of the depolarizing pulses from a holding potential of -50 mV to +10 mV within the range of 100-3000 ms did not affect the extent of I(Kr) block. Carvedilol also inhibited the L-type Ca2+ current (I(Ca)), the transient outward K+ current (I(to)) and the slowly activating component of the delayed rectifier K+ current (I(Ks)) with IC50 of 3.59, 3.34, and 12.54 microM, respectively. Carvedilol (0.3-30 microM) had no significant effects on the inward rectifier K+ current. In papillary muscles from rabbits pretreated with reserpine, action potential duration was prolonged by 7-12% with 1 microM and by 12-24% with 3 microM carvedilol at stimulation frequencies of 0.1-3.0 Hz. No further action potential duration prolongation was observed at concentrations higher than 3 microM. These results suggest that concomitant block of K+ and Ca2+ currents by carvedilol resulted in a moderate prolongation of action potential duration with minimal reverse frequency-dependence. Such electrophysiological effects of carvedilol would be beneficial in the treatment of ventricular tachyarrhythmias.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440104     DOI: 10.1016/s0014-2999(99)00368-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Protective effect of carvedilol on abnormality of L-type calcium current induced by oxygen free radical in cardiomyocytes.

Authors:  Nian Liu; Ronghui Yu; Yanfei Ruan; Qiang Zhou; Jun Pu; Yang Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

2.  Effect of carvedilol on atrial excitation-contraction coupling, Ca2+ release, and arrhythmogenicity.

Authors:  E Martinez-Hernandez; L A Blatter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-04-10       Impact factor: 4.733

3.  Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2010

4.  Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels.

Authors:  K Staudacher; I Staudacher; E Ficker; C Seyler; J Gierten; J Kisselbach; A-K Rahm; K Trappe; P A Schweizer; R Becker; H A Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 5.  Perspectives and challenges of antioxidant therapy for atrial fibrillation.

Authors:  Iveta Gasparova; Peter Kubatka; Radka Opatrilova; Martin Caprnda; Slavomira Filipova; Luis Rodrigo; Leone Malan; Ioana Mozos; Miroslava Rabajdova; Vladimir Nosal; Nazarii Kobyliak; Vanda Valentova; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-29       Impact factor: 3.000

6.  Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy.

Authors:  K Watanabe; Y Ohta; M Nakazawa; H Higuchi; G Hasegawa; M Naito; K Fuse; M Ito; S Hirono; N Tanabe; H Hanawa; K Kato; M Kodama; Y Aizawa
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

7.  Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.

Authors:  Kazunobu Kawakami; Toshihisa Nagatomo; Haruhiko Abe; Kan Kikuchi; Hiroko Takemasa; Blake D Anson; Brian P Delisle; Craig T January; Yasuhide Nakashima
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

8.  Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs.

Authors:  Eue-Keun Choi; Mark J Shen; Shien-Fong Lin; Peng-Sheng Chen; Seil Oh
Journal:  Europace       Date:  2014-01-26       Impact factor: 5.214

9.  Mechanisms of carvedilol-induced [Ca2+] i rises and death in human hepatoma cells.

Authors:  Jin-Shiung Cheng; Chorng-Chih Huang; Chiang-Ting Chou; Chung-Ren Jan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-05       Impact factor: 3.000

10.  Modulation of K2P 2.1 and K2P 10.1 K(+) channel sensitivity to carvedilol by alternative mRNA translation initiation.

Authors:  J Kisselbach; C Seyler; P A Schweizer; R Gerstberger; R Becker; H A Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2014-08-28       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.